Medicinal agents and metabolic syndrome

Current Medicinal Chemistry

Volumn 20, Issue 21, 2013, Pages 2626-2640

  Rubio Ruiz, M E ^a   El Hafidi, M ^a   Perez Torres I ^a   Banos, G ^a   Guarner, V ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Anti inflammatory drugs; Anti oxidant drugs; Lifestyle changes; Medicinal plants; Metabolic syndrome; Pharmacological agents

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHOCYANIN; ATORVASTATIN; CELECOXIB; CIGLITAZONE; CILOSTAZOL; CURCUMIN; ENALAPRIL; FIBRIC ACID DERIVATIVE; HYDROCHLOROTHIAZIDE; INDOMETACIN; ISOTHIOCYANIC ACID DERIVATIVE; LERCANIDIPINE; MELOXICAM; METFORMIN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENTERMINE; PIOGLITAZONE; QUERCETIN; RESVERATROL; ROFECOXIB; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL; UNINDEXED DRUG; URSOLIC ACID;

AEROBIC EXERCISE; ALTERNATIVE MEDICINE; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CALORIC RESTRICTION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DYSLIPIDEMIA; EDEMA; FATTY ACID OXIDATION; FISH; FRUIT; GARLIC; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; GLUCOSE UTILIZATION; HUMAN; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIVER TOXICITY; MEDICINAL PLANT; MEDITERRANEAN DIET; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OSTEOPOROSIS; OVERNUTRITION; PHYSICAL ACTIVITY; RED WINE; SIDE EFFECT; SWEET PEPPER; TEA; THROMBOCYTE AGGREGATION; TOMATO; TRIACYLGLYCEROL BLOOD LEVEL; ULCER; VEGETABLE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; HUMANS; METABOLIC SYNDROME X; MOLECULAR STRUCTURE; PLANT EXTRACTS;

EID: 84880309090     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320210002     Document Type: Article

References (114)

1. Grundy, S.M.; Brewer, H.B.; Cleeman, J.I.; Smith, S.C.; Lenfant, C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation, 2004, 109, 433-438.
2. Rojas, R.; Aguilar-Salinas, C.A.; Jiménez-Corona, A.; Shamah-Levy, T.; Rauda, J.; Avila-Burgos, L.; Villalpando, S.; Ponce, E.L. Metabolic syndrome in Mexican adults: Results from the National Health and Nutrition Survey 2006. Salud Publica Mex., 2010, 52, S11-S18.
3. Olivares-Reyes, J.A.; Plancarte, A.A.; Castillo-Hernandez, J.R. Angiotensin II and the development of insulin resistance: Implications for diabetes. Mol. Cell. Endocrinol., 2008, 302, 128-139.
4. Dandona, P.; Aljada, A.; Bandyopadhyay, A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends. Immunol., 2004, 25(1), 4-7.
5. Morley, J.E. The metabolic syndrome and aging. J. Gerontol. A. Biol. Sci. Med. Sci., 2004, 59(2), 139-142.
6. Kobayasi, R.; Akamine, E.H.; Davel, A.P. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet induced obesity in mice. J. Hypertens., 2010, 28(10), 2111-2119.
7. Eriksson, J.W. Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance. FEBS Lett., 2007, 581, 3734-3742.
8. Edwards, K.M.; Ziegler, M.G.; Mills, P.J. The potential antiinflammatory benefits on improving physical fitness in hypertension. J. Hypertens., 2007, 25, 1533-1542.
9. Reaven, G.M. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: Parallels between human disease and rodent models. Diabetes Care, 1991, 14, 195-202.
10. Pérez-Torres, I.; Roque, P.; El Hafidi, M.; Diaz-Diaz, E.; Baños, G. Association of renal damage and oxidative stress in a rat model of metabolic syndrome. Influence of gender. Free Radic. Res., 2009, 43(8), 761-771.
11. De Ciuceis, C.; Porteri, E.; Rizzoni, D.; Corbellini, C.; La Boria, E.; Boari, G.E.M.; Pilu, A.; Mittempergher, F.; Di Betta, E.; Casella, C.; Nascimbeni, R.; Rosei, C.A.; Ruggeri, G.; Caimi, L.; Rosei, E.A. Effects of weight loss on structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension, 2011, 58, 29-36.
12. Farpour-Lambert, N.J.; Aggoun, Y.; Marchand, L.M.; Martin, X.E.; Herrmann, F.R.; Beghetti, M. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J. Am.Coll.Cardiol., 2009, 54(25), 2396-2406.
13. Cardoso, C.G. Jr.; Gomides, R.S.; Queiroz, A.C.; Pinto, L.G.; da Silveira Lobo, F.; Tinucci, T.; Mion, D. Jr.; de Moraes Forjaz, C.L. Acute and chronic effects of aerobic and resistance exercise on ambulatory blood pressure. Clinics., 2010, 65(3), 317-325.
14. Lehnen, A.M.; Leguisamo, N.M.; Pinto, G.H.; Markoski, M.; De Angelis, K.; Machado, U.F.; Schaan, B. Exercise-stimulated GLUT4 expression is similar in normotensive and hypertensive rats. Horm. Metab. Res., 2011, 43(4), 231-235.
15. Tsarouhas, K.; Tsitsimpikou, C.; Haliassos, A.; Georgoulias, P.; Koutsioras, I.; Kouretas, D.; Kogias, J.; Liosis, I.; Rentoukas, E.; Kyriakides, Z. Study of insulin resistance, TNF-α, total antioxidant capacity and lipid profile in patients with chronic heart failure under exercise. In vivo, 2011, 25(6), 1031-1037.
16. Ahmed, H.M.; Blaha, M.J.; Nasir, K.; Rivera, J.J.; Blumenthal, R.S. Effects of physical activity on CVD. Am. J. Cardiol., 2012, 109(2), 288-295.
17. Bruun, J.M.; Helge, J.W.; Richelsen, B.; Stallknecht, B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am. J. Physiol. Endocrinol. Metab., 2006, 290(5), E961- E967.
18. Petersen, A.M.; Pedersen, B.K. The anti-inflammatory effect of exercise. J. Appl. Physiol., 2005, 98(4), 1154-1162.
19. Starkie, R.; Ostrowski, S.R.; Jauffred, S.; Febbraio, M.; Pedersen, B.K. Exercise and IL-6 infusion inhibit endotoxin-induced TNFalpha production in humans. FASEB J., 2003, 17(8), 884-886.
20. Capurso, C.; Capurso, A. From excess adiposity to insulin resistance: The role of free fatty acids. Vascul. Pharmacol., 2012, doi:10.1016/j.vph.2012.05. 003
21. Holloszy, J.O.; Coyle, E.F. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J. Appl. Physiol., 1984, 56(4), 831-838.
22. Aoi, W.; Naito, Y.; Yoshikawa, T. Dietary exercise as a novel strategy for the prevention and treatment of metabolic syndrome: Effects on skeletal muscle function. J. Nutr. Metab., 2011, doi:10.1155/2011/676208
23. Wallace, M.A.; Hock, M.B.; Hazen, B.C.; Kralli, A.; Snow, R.J.; Russell, A.P. Striated muscle activator of Rho signalling (STARS) is a PGC-1β/oestrogen-related receptor-k target gene and is upregulated in human skeletal muscle after endurance exercise. J. Physiol., 2011, 589(Pt 8), 2027-2039.
24. Hoene, M.; Lehmann, R.; Hennige, A.M.; Pohl, A.K.; Häring, H.U.; Schleicher, E.D.; Weigert, C. Acute regulation of metabolic genes and insulin receptor substrates in the liver of mice by one single bout of treadmill exercise. J. Physiol., 2009, 587(Pt 1), 241-252.
25. Fritz, T.; Krämer, D.K.; Karlsson, H.K.; Galuska, D.; Engfeldt, P.; Zierath, J.R.; Krook, A. Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients. Diabetes Metab. Res. Rev., 2006, 22(6), 492-498.
26. Hawley, J.A.; Lessard, S.J. Exercise training-induced improvements in insulin action. Acta Physiol., 2008, 192(1), 127-135.
27. Layne, A.S.; Nasrallah, S.; South, M.A.; Howell, M.E.; McCurry, M.P.; Ramsey, M.W.; Stone, M.H.; Stuart, C.A. Impaired muscle AMPK activation in the metabolic syndrome may attenuate improved insulin action after exercise training. J. Clin. Endocrinol. Metab., 2011, 96(6), 1815-1826.
28. Richter, E.A.; Ruderman, N.B. AMPK and the biochemistry of exercise: Implications for human health and disease. Biochem. J., 2009, 418(2), 261-275.
29. Hegarty, B.D.; Turner, N.; Cooney, G.J.; Kraegen, E.W. Insulin resistance and fuel homeostasis: The role of AMP-activated proteinkinase. Acta Physiol., 2009, 196(1), 129-145.
30. Martínez-Florez, S.; Gutiérrez, F.B.; Sánchez, C.S.; González, G.J.; Tuñón, M.J.; Quercetin attenuates nuclear factor-kB activation and nitric oxide production in interleukin-1β- activated rat hepatocytes. J. Nutr., 2005, 135, 1359-1365.
31. Tang, D.; Kang, R.; Xiao, W.; Zhang, H.; Lotze, M.T.; Wang, H.; Xiao, X. Quercetin prevents LPS-induced high-mobility group Box 1 release and proinflammatory function. Am. J. Respir. Cell. Mol. Biol., 2009, 41,651-660.
32. Na, H.K.; Kim, E.H.; Jung, J.H.; Lee, H.H.; Hyun, J.W.; Surh, Y.J. -(-) Epigallocatechin gallate induces Nrf2-mediated antioxidant enzyme expression via activation of PI3K and ERK in human mammary epithelial cells. Arch. Biochem. Biophys., 2008, 476, 171-177.
33. Surh, Y.J.; Na, H.K. NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with antinflammatory and antioxidant phytochemicals. Genes. Nutr., 2008, 2, 313-317.
34. Ungvari, Z.; Bagi, Z.; Feher, A.; Recchia, F.A.; Sonntag, W.E.; Pearson, K.; de Cabo, R.; Csiszar, A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart. Circ. Physiol., 2010, 299, H18-H24.
35. Perez-Torres, I.; Ruiz-Ramirez, A.; Baños, G.; El Hafidi, M. Hibiscus Sabdariffa Linnaeus (Malvacae), curcumin and resveratrol as alternative medicinal agents against metabolic syndrome. Cardiovasc. Hematol. Agents Med. Chem., 2012, doi:10.1016/j.tem.2012.06.008.
36. Keum, Y.S.; Chang, P.P.J.; Kwon, K.H.; Yuan, X.; Li, W.; Hu, L.; Kong, T.A. 3-Morpholinopropyl isothiocyanate is a novel synthetic isothiocyanate that strongly induces the antioxidant response element-dependent Nrf2-mediated detoxifying/antioxidant enzymes in vitro and in vivo. Carcinogenesis, 2008, 29, 594-599.
37. Kunkel, S.D.; Elmore, C.J.; Bongers, K.S.; Ebert, S.M.; Fox, D.K.; Dyle, M.C.; Bullard S.A.; Adams, C.M. Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS ONE 2012, 7(6):e39332. doi:10.1371/journal.pone.0039332.
38. Rao, V.S.; de Melo, C.L.; Queiroz, M.G.; Lemos, T.L.; Menezes, D.B.; Melo, T.S.; Santos, F.A. Ursolic acid, a pentacyclic triterpene from Sambucus australis, prevents abdominal adiposity in mice fed a high-fat diet. J. Med. Food, 2011, 14(11), 1375-1382.
39. Chen J.; Lei, Y.; Wu, G.; Zhang, Y.; Fu, W.; Xiong, C.; Ruan, J. Renoprotective potential of Macrothelypteris torresiana via ameliorating oxidative stress and proinflammatory cytokines. J. Ethnopharmacol., 2012, 139(1), 207-213.
40. Huang, X.H.; Xiong, P.C.; Xiong, C.M.; Cai, Y.L.; Wei, A.H.; Wang, J.P.; Liang, X.F.; Ruan, J.L. In vitro and in vivo antitumor activity of Macrothelypteris torresiana and its acute/subacute oral toxicity. Phytomedicine, 2010, 17(12), 930-934.
41. Hunyadi, A.; Chuang, D.W.; Danko, B.; Chiang, M.Y.; Lee, C.L.; Wang, H.C.; Wu, C.C.; Chang, F.R.; Wu, Y.C. Direct semisynthesis of the anticancer lead-drug protoapigenone from apigenin, and synthesis of further new cytotoxic protoflavone deriva tives. PLoS ONE 2011, 6(8):e23922. doi:10.1371/journal.pone. 0023922.
42. Liu, H.; Jiang, C.; Xiong, C.; Ruan, J. DEDC, a new flavonoid induces apoptosis via a ROS-dependent mechanism in human neuroblastoma SH-SY5Y cells. Toxicology in vitro, 2012, 26, 16-23.
43. Martin, C.; Butelli, E.; Petroni, K.; Tonelli, C. How can research on plants contribute to promoting human health? The Plant Cell, 2011, 23, 1685-1699.
44. Reilly, M.P.; Reader, D.J. The metabolic syndrome. More than the sum of its parts? Circulation, 2003, 108, 1546-1551.
45. Anfossi, G.; Russo, I.; Trovati, M. Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis., 2009, 19(6), 440-449.
46. Mirrakhimov, A.E.; Kerimkulova, A.S.; Lunegova, O.S.; Moldokeeva, C.B.; Zalesskaya, Y.B.; Abilova, S.S.; Sovhozova, N.A.; Aldashev, A.A.; Mirrakhimov, E.M. An association between TRP64ARG polymorphism of the B3 adrenoreceptor gene and some metabolic disturbances. Cardiovascular Diabetology, 2011, 10, 89.
47. Dionne, I.J.; Garant, M.J.; Nolan, A.A.; Pollin, T.I.; Lewis, D.G.; Shuldiner, A.R.; Poehlman, E.T. Association between obesity and a polymorphism in the b1-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. International Journal of Obesity, 2002, 26, 633-639.
48. Deedwania, P.C.; Gupta, R. Management issues in the metabolic syndrome. J. Assoc. Physicians. India. 2006, 54, 797-810.
49. Grundy, S.M. Metabolic syndrome: Therapeutic considerations. Handb. Exp. Pharmacol. 2005, 170, 107-133.
50. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New. Biol., 1971, 231, 232-235.
51. Glasser, S.P.; Cushman, M.; Prineas, R.; Kleindorfer, D.; Prince, V.; You, Z.; Howard, V.J.; Howard, G. Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? Prev. Med., 2008, 47(2), 161-166.
52. Hawkey, C.J. COX-1 and COX-2 inhibitors. Best. Pract. Res. Clin. Gastroenterol., 2001, 15(5),801-820.
53. Dangas, G.D., Claessen, B.E., Mehran, R., Xu, K., Stone, G.W. Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: Results of the HORIZONS-AMI trial. EuroIntervention, 2013, 8(9), 1033-1039.
54. Wu, R.; Lamontagne, D.; de Champlain, J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation, 2002, 105, 387-392.
55. Deng, S. ; Deng, P.Y. ; Jiang, J.L. ; Ye, F. ; Yu, J. ; Yang, T.L. ; Deng, H.D. ; Li, Y.J. Aspirin protected against endothelial damage induced by LDL: Role of endogenous NO synthase inhibitors in rats. Acta Pharmacol. Sin., 2004, 25(12), 1633-1639.
56. Zhang, L.; Zheng, J.; Li, H.M.; Meng, Y.X. Inhibitory effects of cardiotonic pills on platelet function in dogs fed a high-fat diet. Blood Coagul. Fibrinolysis, 2006, 17(4), 259-264.
57. Park, E.; Wong, V.; Guan, X.; Oprescu, A.I.; Giacca, A. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J. Endocrinol., 2007, 195(2), 323-331.
58. Van Gaal, L.F.; Mertens, I.L.; De Block, C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444, 875-880.
59. Hainer, V.; Hainerová, I.A. Do we need anti-obesity drugs? Diabetes Metab. Res. Rev. 2012, 28 Suppl 2, 8-20.
60. Adan, R.A. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 2013, 36(2), 133-140.
61. www.fda.gov/ForConsumers/ConsumerUpdates/ucm312380.htm
62. Fajas, L.; Miard, S.; Briggs, M.R.; Auwerx, J. Selective cyclooxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase. J. Lipid. Res., 2003, 44(9), 1652-1659.
63. Kotronen, A.; Yki-Jarvinen, H. Fatty Liver: A novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 27-38.
64. Vos, M.B.; Lavine, J.E. Dietary fructose in nonalcoholic fatty liver disease. Hepatology, 2013, doi: 10.1002/hep.26299.
65. Fujita, K.; Nozaki, Y.; Wada, K.; Yoneda, M.; Endo, H.; Takahashi, H.; Iwasaki, T.; Inamori, M.; Abe, Y.; Kobayashi, N.; Kirikoshi, H.; Kubota, K.; Saito, S.; Nagashima, Y.; Nakajima, A. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut., 2008, 57(11), 1583-1591.
66. Cornier, M.A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; Van Pelt, R.E.; Wang, H.; Eckel, R.H. The metabolic syndrome. Endocrine Reviews, 2008, 29, 777-822.
67. Huacuja-Álvarez, F.; Gómez Duque, M.; Ortiz Vargas, J.C.; Soberanes-Velázquez, B.; Arévalo-Moreno, V.; Morales-Villegas, E.; Sánchez-Reyes, L.; Fanghänel, G. Efecto de las estatinas más allá del colesterol. Revista de Endocrinología y Nutrición, 2006, 14(2), 73-88.
68. Meyer-Sabellek, W.; Brasch, H. Atherosclerosis, inflammation, leukocyte function and the effect of statins. J. Hypertens., 2006, 24, 2349-2351.
69. Zambon, A.; Gervois, P.; Pauletto, P.; Fruchart, J.C.; Staels, B. Modulation of hepatic inflammatory risk markers of CVD by PPAR-α activators: Clinical and experimental evidence. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 977-986.
70. Athyros, V.G.; Tziomalos, K.; Mikhailidis, D.P.; Pagourelias, E.D.; Kakafika, A.I.; Skaperdas, A.; Hatzitolios, A.; Karagiannis, A. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert. Opin. Pharmacother., 2007, 8(14), 2267-2277.
71. Kadowaki, T.; Yamauchi, T.; Kubota, N.; Hara, K.; Ueki, K.; Tobe, K. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J. Clin. Invest., 2006, 116, 1784-1792.
72. Samaha, F.F.; Szapary, P.O.; Iqbal, N.; Williams, M.M.; Bloedon, L.T.; Kochar, A.; Wolfe, M.L.; Rader, D.J. Effects of Rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with Low High-Density lipoprotein cholesterol and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 624-630.
73. Bashmakov, Y.K.; Petyaev, I.M. Old drug acquires new target: Metformin and Sirt1. J. Diabetes. Metab., 2011, 2:107e. doi:10.4172/2155-6156.1000107e
74. Tchernof, A., Després, J.P. Pathophysiology of human visceral obesity: An update. Physiol. Rev. 2013, 93(1), 359-404.
75. Singh, S.; Loke, Y.K.; Furberg, C.D. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA, 2007, 298, 1189-1195.
76. Forman, L.M.; Simmons, D.A.; Diamond, R.H. Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med., 2000, 132(2), 118-121.
77. Boelsterli, U.A.; Bedoucha, M. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: Insights from models of obesity and type 2 diabetes. Biochem. Pharmacol., 2002, 63,1-10.
78. Meier, C.; Kraenzlin, M.E.; Bodmer, M.; Jick, S.S.; Jick, H.; Meier, C.R. Use of thiazolidinediones and fracture risk. Arch. Intern. Med. 2008, 168, 820-825.
79. Berria, R.; Glass, L.; Mahankali, A.; Miyazaki, Y.; Monroy, A.; De Filippis, E.; Cusi, K.; Cersosimo, E.; Defronzo, R.A.; Gastaldelli, A. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin. Pharmacol. Ther. 2007, 82 (3), 275-281.
80. Zhang, J.; Wang, J.; Wu, H.; He, Y.; Zhu, G.; Cui, X.; Tang, L. Design, synthesis and insulin-sensitizing activity of indomethacin and diclofenac derivatives. Bioorg. Med. Chem. Lett., 2009, 19(12), 3324-3327.
81. Hayashi, K.; Wakino, S.; Sugano, N.; Ozawa, Y.; Homma, K.; Saruta, T. Ca2+ channel subtypes and pharmacology in the kidney. Circ. Res., 2007, 100, 342-353.
82. Amenta, F.; Peleg, E.; Tomassoni, D.; Sabbatini, M.; Rosenthal, T. Effect of treatment with lercanidipine on heart of cohen-rosenthal diabetic hypertensive rats. Hypertension, 2003, 41, 1330-1335.
83. Pruijm, M.T.; Maillard, M.P.; Burnier, M. Patient adherence and the choice of antihypertensive drugs: Focus on lercanidipine. Vasc. Health Risk Manag., 2008, 4(6), 1159-1166.
84. Menne, J.; Park, J. K.; Agrawal, R.; Lindschau, C.; Kielstein, J.T.; Kirsch, T.; Marx, A.; Muller, D.; Bahlmann, F.H.; Meier, M.; Bode-Böger, S.M.; Haller, H.; Fliser, D. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J., 2006, 20, 994-996.
85. Snider, M.E.; Nuzum, D.S.; Veverka, A. Long-acting nifedipine in the management of the hypertensive patient. Vasc. Health Risk Manag., 2008, 4(6), 1249-1257.
86. Philipp, T.; Smith, T.R.; Glazer, R.; Wernsing, M.; Yen, J.; Jin, J.; Schneider, H.; Pospiech, R. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther., 2007, 29(4), 563-580.
87. Borghi, C.; Santi, F. Fixed combination of lercanidipine and enalapril in the management of hypertension: Focus on patient preference and adherence. Patient Prefer. Adherence., 2012, 6, 449-455.
88. Nakamura, T.; Fujiwara, N.; Kawagoe, Y.; Sugaya, T.; Ueda, Y.; Koide, H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur. J. Clin. Invest., 2010, 40(9), 790-796.
89. Kohlstedt, K.; Gershome, C.; Trouvain, C.; Hofmann, W.K.; Fichtlscherer, S.; Fleming, I. Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol. Pharmacol., 2009, 75, 685-692.
90. Chin, B.S.P.; Langford, N.J.; Nuttall, S.L.; Gibbs, C.R.; Blann, A.D.; Lip, G.Y.H. Anti-oxidative properties of beta-blockers and angiotensin- converting enzyme inhibitors in congestive heart failure. Eur. J. Heart Fail., 2003, 5(2), 171-174.
91. Reid, J.L. Review: Molecular-specific effects of angiotensin II antagonists: Clinical relevance to treating hypertension? J. RAS., 2005, 6, 15-24.
92. Sugimoto, K.; Qi, N.R.; Kazdová, L.; Pravenec, M.; Ogihara, T.; Kurtz, T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension, 2006, 47, 1003-1009.
93. Oparil, S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am. J. Hypertens., 2000, 13(1 Pt 2), 18S-24S.
94. Oparil, S., Michelson, E.L. Long term efficacy, safety, and tolerability of candesartan cilexitil added to hydrochlorothiazide in patients with severe hypertension. Am. J. Hypertens., 2009, 12,120.
95. Al-Thanoon, Z.A., Mahmood, I.H. Effects of losartan vs. enalapril on the markers of metabolic syndrome. Oman. Med. J., 2012, 27(1), 27-30.
96. Borghi, C.; Cicero, A.F. The role of irbesartan in the treatment of patients with hypertension: A comprehensive and practical review. High Blood Press. Cardiovasc. Prev., 2012, 19(1), 19-31.
97. Miura, S.; Kiya, Y.; Kanazawa, T.; Imaizumi, S.; Fujino, M.; Matsuo, Y.; Karnik, S.S.; Saku, K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol. Endocrinol., 2008, 22(1), 139-146.
98. Manabe, S.; Okura, T.; Watanabe, S.; Fukuoka, T.; Higaki, J. Effects of angiotensin II receptor blockade with valsartan on proinflammatory cytokines in patients with essential hypertension. J. Cardiovasc. Pharmacol., 2005, 46(6), 735-739.
99. Rompe, F.; Artuc, M.; Hallberg, A.; Alterman, M.; Ströder, K.; Thöne-Reineke, C.; Reichenbach, A.; Schacherl, J.; Dahlöf, B.; Bader, M.; Alenina, N.; Schwaninger, M.; Zuberbier, T.; Funke-Kaiser, H.; Schmidt, C.; Schunck, W.H.; Unger, T.; Steckelings, U.M. Direct Angiotensin II type 2 receptor stimulation acts antiinflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor-kB. Hypertension, 2010, 55, 924-931.
100. Priebe, H.J. Influence of beta-blockers on the outcome of at risk patients. Minerva Anestesiol., 2009, 75(5), 319-323.
101. Ellison, D.H.; Loffing, J. Thiazide effects and adverse effects: Insights from molecular genetics. Hypertension, 2009, 54, 196-202.
102. Manrique, C.; Johnson, M.; Sowers, J.R. Thiazide diuretics alone or with k-Blockers impair glucose metabolism in hypertensive patients with abdominal obesity. Hypertension, 2010, 55, 15-17.
103. Reungjui, S.; Roncal, C.A.; Mu, W.; Srinivas, T.R.; Sirivongs, D.; Johnson, R.J.; Nakagawa, T. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J. Am. Soc. Nephrol., 2007, 18, 2724-2731.
104. Bramlage, P.; Schonrock, E.; Odoj, P.; Wolf, W.P.; Funken, C. Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ. MMW Fortschritte der Medizin, 2008, 149(Suppl 4), 172-181.
105. Harris, R.C. An update on cyclooxygenase-2 expression and metabolites in the kidney. Curr. Opin. Nephrol. Hypertens., 2008, 17(1), 64-69.
106. Wilson, S.L.; Poulter, N.R. The effect of non-steroidal antiinflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J. Hypertens., 2006, 24, 1457-1469.
107. White, W.B. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension, 2007, 49, 408-418.
108. Alvarez-Nemegyei, J.; Rubio-Solís, E.N.J.; Herrera-Correa, G.M. Efecto del tratamiento a corto plazo con antiinflamatorios no esteroideos en la presión arterial media. Un ensayo clínico aleatorizado. Reumatol. Clin., 2006, 2(1), 10-14.
109. Bulckaen, H.; Prévost, G.; Boulanger, E.; Robitaille, G.; Roquet, V.; Gaxatte, C.; Garçon, G.; Corman, B.; Gosset, P.; Shirali, P.; Creusy, C.; Puisieux, F. Low-dose aspirin prevents age-related endothelial dysfunction in a mause model of physiological aging. Am. J. Physiol. Heart. Circ. Physiol., 2008, 294, H1562-H1570.
110. Raghavan, R.P.; Laight, D.W.; Shaw, K.M.; Cummings, M.H. Aspirin and diabetes. Br. J. Diabetes Vasc. Dis., 2006, 6, 74-82.
111. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Invest., 2006, 116(7), 1793-1801.
112. Fernández-Real, J.M.; Ricart, W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews, 2003, 24, 278-301.
113. Reboldi, G.; Gentile, G.; Angeli, F.; Verdecchia, P. Choice of ACE inhibitor combinations in hypertensive patients with type-2 diabetes: Update after recent clinical trials. Vasc. Health Risk Manag., 2009, 5(1), 411-427.
114. Mengden, T.; Uen, S.; Bramlage, P. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: Patient perspectives and clinical utility. Vasc. Health Risk Manag., 2009, 5, 1043-1058.